Search
Elamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigational[A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction.
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalDerived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. … It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigationalDolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Digoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexPyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawnRemoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors. … [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Mogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigational) or Sézary syndrome (SS) after at least one prior systemic therapy. … Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of
Potassium acetate
go.drugbank.com/drugs/DB14498ApprovedMixtures: Normosol-M and Dextrose, Normosol-M and DextroseHuman cytomegalovirus immune globulin
go.drugbank.com/drugs/DB13886ApprovedInvestigationalAs a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229]. … Cytomegalovirus (CMV) may lead to a wide spectrum of infection in immunocompetent hosts.